Drugs / Human Urinary Kallidinogenase for Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02806128 | Nov 2016 → Dec 2018 | cerebral infarction | Huisheng Chen | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Urinary Kallidinogenase for Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02806128 ↗ |
| Known as | KLK | “Injection of Human Urinary Kallidinogenase for Injection (KLK) three times a day, 14 days .” NCT02806128 ↗ |